Investigational drug · Phase 3
ZG006
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
11
Any phase or sponsor naming "ZG006"
First trial start
2023
Oct 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZG006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neuroendocrine Carcinoma
- Small Cell Lung Cancer
- Solid Tumor
- Small-cell Lung Cancer
- Neuroendocrine Prostate Cancer
- Neuroendocrine Cancer
Approved drugs for the same conditions: Small cell lung cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ZG006" as an intervention, largest first.
- Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07189455 · 420 participants (planned) · Start Dec 12, 2025 · Primary completion Oct 2028
Drug: ZG006; Topotecan · For: Small-cell Lung Cancer
Sites: Shanghai, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07258121 · 400 participants (planned) · Start Dec 31, 2025 · Primary completion Dec 2028
Drug: ZG006 · For: Solid Tumor
Sites: Zhengzhou, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07038096 · 350 participants (planned) · Start Sep 23, 2025 · Primary completion Sep 2027
Drug: ZG006; ZG005 · For: Small Cell Lung Cancer; Neuroendocrine Carcinoma
Sites: Guanzhou, China
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07892625 · 338 participants (planned) · Start Nov 15, 2026 · Primary completion Sep 15, 2028
Drug: HS-20093 for Injection; ZG006 and 1 more · For: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06283719 · 265 participants (planned) · Start Sep 2, 2024 · Primary completion Apr 2027
Drug: ZG006 · For: Small Cell Lung Cancer; Neuroendocrine Cancer
Sites: Shanghai, China
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaPivotal-lookingNot yet recruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07595913 · 240 participants (planned) · Start Jul 2026 · Primary completion Jun 2028
Drug: ZG006; 5-fluorouracil, Calcium folinate and Irinotecan · For: Neuroendocrine Carcinoma
Sites: Zhengzhou, China
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07231445 · 100 participants (planned) · Start Apr 21, 2026 · Primary completion Dec 2028
Drug: ZG006; Serplulimab · For: Small Cell Lung Cancer
Sites: Shanghai, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06440057 · 78 participants (planned) · Start Aug 29, 2024 · Primary completion May 2026
Drug: ZG006 · For: Neuroendocrine Carcinoma
Sites: Beijing, China
- Study of ZG006 in Participants With Neuroendocrine Prostate CancerNot yet recruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07024277 · 60 participants (planned) · Start Aug 2025 · Primary completion Dec 2027
Drug: ZG006 · For: Neuroendocrine Prostate Cancer
Sites: Shanghai, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT05978284 · 54 participants (planned) · Start Oct 27, 2023 · Primary completion Sep 2026
Drug: ZG006 · For: Small Cell Lung Cancer; Neuroendocrine Carcinoma
Sites: Zhengzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Neuroendocrine Carcinoma
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.